Rangering i aksjer
#33713
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Aksjekurs
$0.4732
Sist synkronisert: 2022-10-26
Pris GBS pris med markedsverdi på B
Markedsverdi av GBS Inc.(GBS)
Markedsverdi: $7.05M
Per August 2026 har GBS Inc. en markedsverdi på $7.05M. Dette gjør GBS Inc. til det 33713th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for GBS Inc. fra 2020 til 2026
GBS sammenlignet med topp 5 mest populære stocks
| Pris på GBS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+77,373,417.78%
|
|
|
|
|
$4.490T
|
+63,722,769.37%
|
|
|
|
|
$4.162T
|
+59,073,246.83%
|
|
|
|
|
$3.676T
|
+52,174,963.85%
|
|
|
|
|
$2.833T
|
+40,206,758.40%
|
